Sugi Predict

Sugi Predict / Compounds / SCHEMBL12791106

SCHEMBL12791106

SCHEMBL12791106

N[C@H]1CCCN(C(=O)OCc2ccccc2)C1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.60
▸ CYP2C19 P33261 1/20 0.60
▸ NPC1 O15118 2/20 0.59
▸ RAB9A P51151 2/20 0.59
▸ MEN1 O00255 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ JAK2 O60674 2/20 0.50
▸ JAK1 P23458 2/20 0.50
▸ TYK2 P29597 2/20 0.50
▸ JAK3 P52333 2/20 0.50
▸ PDE4B Q07343 1/20 0.48
▸ GRIN2B Q13224 3/20 0.48
▸ HTT P42858 1/20 0.48
▸ USP30 Q70CQ3 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ PREP P48147 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL764193 1.00 SMN1; SMN2 (0.60) SMN1; SMN2CYP2C19NPC1RAB9AMEN1
SCHEMBL654999 1.00 SMN1; SMN2 (0.60) SMN1; SMN2CYP2C19NPC1RAB9AMEN1
Hydrochloric Acid SCHEMBL653531 0.99 SMN1; SMN2 (0.59) SMN1; SMN2CYP2C19NPC1RAB9AMEN1
Hydrochloric Acid SCHEMBL27097154 0.97 SMN1; SMN2 (0.57) SMN1; SMN2CYP2C19NPC1RAB9AMEN1
SCHEMBL6523477 0.96 SMN1; SMN2 (0.59) SMN1; SMN2CYP2C19NPC1RAB9AMEN1
SCHEMBL1562901 0.96 SMN1; SMN2 (0.59) SMN1; SMN2CYP2C19NPC1RAB9AMEN1
SCHEMBL6524693 0.92 SMN1; SMN2 (0.67) SMN1; SMN2CYP2C19NPC1RAB9AMEN1
SCHEMBL266047 0.92 SMN1; SMN2 (0.67) SMN1; SMN2CYP2C19NPC1RAB9AMEN1
SCHEMBL3617580 0.92 SMN1; SMN2 (0.67) SMN1; SMN2CYP2C19NPC1RAB9AMEN1
SCHEMBL1189968 0.92 SMN1; SMN2 (0.67) SMN1; SMN2CYP2C19NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3712262-B1 TRANSAMINASE MUTANT AND APPLICATION THEREOF ASYMCHEM LIFE SCIENCE TIANJIN CO LTD (CN) 2025-05-21 — — EP disclosed
US-20240408064-A1 RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF GENETOLEAD INC. (CA) 2024-12-12 — — US disclosed
US-12071425-B2 Phenoxy-pyridyl-pyrimidine compounds and methods of use GENENTECH, INC. (US) 2024-08-27 — — US disclosed
US-11952575-B2 Transaminase mutant and use thereof ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD (CN) 2024-04-09 — — US disclosed
CN-111278840-B Pyrrolo [2,3-B ] pyridine compounds and their use for the treatment of cancer 癌症研究科技有限公司 2023-11-17 — — CN disclosed
WO-2023060362-A1 RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF GENETOLEAD INC. (CA) 2023-04-20 — — WO disclosed
US-20230057166-A1 PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2023-02-23 — — US disclosed
US-11447505-B1 Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2022-09-20 — — US disclosed
CN-112094830-B Transaminase mutants and uses thereof 凯莱英生命科学技术(天津)有限公司 2022-06-24 — — CN disclosed
WO-2022075974-A1 CYCLIC TREX1 INHIBITORS Venenum Biodesign, LLC (US) 2022-04-14 — — WO disclosed
CN-108048419-B Transaminase mutants and uses thereof 凯莱英生命科学技术(天津)有限公司 2020-10-23 — — CN disclosed
EP-3712262-A1 TRANSAMINASE MUTANT AND APPLICATION THEREOF Asymchem Life Science (Tianjin) Co., Ltd. (CN) 2020-09-23 — — EP disclosed
US-20200239895-A1 TRANSAMINASE MUTANT AND USE THEREOF ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD (CN) 2020-07-30 — — US disclosed
CN-111278840-A Pyrrolo [2, 3-B ] pyridine compounds and their use for treating cancer 癌症研究科技有限公司 2020-06-12 — — CN disclosed
WO-2011029804-A1 INHIBITORS OF JAK F. HOFFMANN-LA ROCHE AG (CH) 2011-03-17 — — WO disclosed
US-20110059118-A1 INHIBITORS OF JAK DE VICENTE FIDALGO JAVIER 2011-03-10 — — US disclosed
US-20110059118-A1 INHIBITORS OF JAK DE VICENTE FIDALGO JAVIER 2011-03-10 — — US disclosed
US-20100056497-A1 AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2010-03-04 — — US disclosed
US-20100056497-A1 AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2010-03-04 — — US disclosed
EP-2119702-A1 AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-11-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230057166-A1 PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE XBP1, ERN1, ESR2 SMN1; SMN2 1892/4885CYP2C19 1981/4885NPC1 1937/4885
US-12071425-B2 Phenoxy-pyridyl-pyrimidine compounds and methods of use XBP1, ERN1, ESR2 SMN1; SMN2 1892/4885CYP2C19 1981/4885NPC1 1937/4885
US-20240408064-A1 RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF KRAS, NRAS, HRAS SMN1; SMN2 3808/4885CYP2C19 3676/4885NPC1 2287/4885
US-20110059118-A1 INHIBITORS OF JAK JAK1, JAK3, JAK2 SMN1; SMN2 4714/4885CYP2C19 2766/4885NPC1 3749/4885
US-11447505-B1 Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer PDXK, CCNK, CDC42BPB SMN1; SMN2 2979/4885CYP2C19 2014/4885NPC1 2823/4885
US-20100056497-A1 AMIDE DERIVATIVE REN, AGTR1, AGTR2 SMN1; SMN2 3574/4885CYP2C19 262/4885NPC1 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.